0
0
This Good practice statement has been developed on the basis of advice issued by the Strategic Advisory Group of Experts (SAGE) on Immunization at its meeting on 5 October 2022, and was updated on 20 February 2023 based on additional evidence and advice by SAGE. Declarations of interests were collected from all external contributors and assessed for any conflicts of interest. Summaries of the reported interests can be found on the SAGE meeting website and SAGE Covid-19 Working Group webpage.
This guidance should be considered along with the broader COVID-19 policy advice to WHO member states and in particular the advice on how to reach the COVID-19 vaccination targets. Other referenced documents are available on the SAGE COVID-19 webpage: www.who.int/groups/strategic-advisory-group-of-experts-on-immunization/covid-19-materials This Good Practice Statement summarizes current evidence on variant-containing vaccines and provides guidance on their use in the context of the continued availability of ancestral virus-only (monovalent) COVID-19 vaccines.
Download Here
Good practice statement on the use of variant-containing COVID-19 vaccines
